S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
NASDAQ:IDXX

IDEXX Laboratories - IDXX Stock Forecast, Price & News

$482.41
-21.81 (-4.33%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$478.21
$497.38
50-Day Range
$399.93
$504.22
52-Week Range
$317.06
$560.92
Volume
817,322 shs
Average Volume
614,384 shs
Market Capitalization
$39.95 billion
P/E Ratio
61.30
Dividend Yield
N/A
Price Target
$485.00

IDEXX Laboratories MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
0.5% Upside
$485.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.80
Upright™ Environmental Score
News Sentiment
0.69mentions of IDEXX Laboratories in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$12.54 M Sold Last Quarter
Proj. Earnings Growth
19.62%
From $7.90 to $9.45 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

446th out of 1,029 stocks

Diagnostic Substances Industry

7th out of 15 stocks

IDXX stock logo

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in West

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

GE HealthCare Technologies Soars As GE Legacy Business Plummets (IDXX)
Wednesday marked the trading debut of GE HealthCare Technologies, the health-focused business spun off from General Electric. Shares rose 12%.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
A Preview Of IDEXX Laboratories's Earnings
IDEXX Laboratories Q4 2022 Earnings Preview
SONVY or IDXX: Which Is the Better Value Stock Right Now?
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
IDEXX Laboratories Is Barking Up the Right Tree
11 Best Pet Stocks To Buy Now
IDEXX Laboratories: Not Enough Visibility, Hold
Massive Insider Trade At IDEXX Laboratories
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Company Calendar

Last Earnings
11/02/2021
Today
2/03/2023
Next Earnings (Confirmed)
2/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
10,350
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$485.00
High Stock Price Forecast
$582.00
Low Stock Price Forecast
$415.00
Forecasted Upside/Downside
+0.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
8 Analysts

Profitability

Net Income
$744.84 million
Pretax Margin
25.11%

Debt

Sales & Book Value

Annual Sales
$3.22 billion
Cash Flow
$10.00 per share
Book Value
$8.14 per share

Miscellaneous

Free Float
81,111,000
Market Cap
$39.95 billion
Optionable
Optionable
Beta
1.17

Social Links


Key Executives

  • Jonathan J. MazelskyJonathan J. Mazelsky
    President, Chief Executive Officer & Director
  • Brian Patrick McKeon
    Chief Financial Officer, Treasurer & Executive VP
  • Ken Grady
    Chief Information Officer & Senior VP
  • Murthy Yerramilli
    Senior Vice President-Research & Development
  • Martin Alexander Smith
    Chief Technology Officer & Executive VP













IDXX Stock - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price forecast for 2023?

8 Wall Street analysts have issued twelve-month price targets for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $582.00. On average, they expect the company's stock price to reach $485.00 in the next twelve months. This suggests a possible upside of 0.5% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2023?

IDEXX Laboratories' stock was trading at $407.96 at the start of the year. Since then, IDXX stock has increased by 18.2% and is now trading at $482.41.
View the best growth stocks for 2023 here
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023.
View our IDXX earnings forecast
.

How can I listen to IDEXX Laboratories' earnings call?

IDEXX Laboratories will be holding an earnings conference call on Monday, February 6th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its earnings results on Tuesday, November, 2nd. The company reported $2.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.88 by $0.15. The firm had revenue of $810.42 million for the quarter, compared to analysts' expectations of $793.26 million. IDEXX Laboratories had a trailing twelve-month return on equity of 118.38% and a net margin of 20.05%. During the same period in the prior year, the business posted $1.69 earnings per share.
Read the conference call transcript
.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of $7.74-$7.98 for the period, compared to the consensus earnings per share estimate of $7.95. The company issued revenue guidance of $3.33 billion-$3.37 billion, compared to the consensus revenue estimate of $3.37 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by many different institutional and retail investors. Top institutional shareholders include LGT Capital Partners LTD. (0.38%), UMB Bank n.a. (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Manning & Napier Group LLC (0.21%), Welch & Forbes LLC (0.21%) and Bank Julius Baer & Co. Ltd Zurich (0.20%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $482.41.

How much money does IDEXX Laboratories make?

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $39.95 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $7.87 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

The company employs 10,350 workers across the globe.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 2/4/2023 by MarketBeat.com Staff